The active component of this medicine is Hydroxyurea. This ingredient is a mono hydroxyl-substituted urea antimetabolite that inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates. It acts to prevent the cells from leaving the G1/S phase of the cell cycle. It exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive phase and replicating with DNA repair.
The active component is an antimetabolite used in the treatment of cancer and to stimulate fetal hemoglobin production in sickle cell disease. It is related to a low rate of transient serum enzyme and bilirubin elevations during therapy.
This medication is indicated in people with sickle cell anemia to reduce the number of painful crises. This condition is caused by the disease and reduces the need for blood transfusions. Hydrea can also be used to treat certain types of cancer like chronic myelogenous leukemia and squamous cell carcinomas.
The active component Hydroxyurea is also called Hydroxycarbamide. This ingredient is converted to a free radical nitroxide in vivo, and transferred by diffusion into cells where it quenches the tyrosyl free radical at the active site of the M2 protein subunit of ribonucleotide reductase, inactivating the enzyme.
- Hematological Disorder
- Gastrointestinal Disorder
- Eating Disorder
- Loss Of Appetite
This mentioned medication Hydrea is composed as a capsule for oral consumption and made available in a dosage as given below:
- 500 mg: It is indicated for oral administration once a day with or without food as directed by the doctor.
This medication can be absorbed through the skin and lungs, pregnant or nursing women should not handle this medication or breathe the dust from the capsules.